AB0124

☆ Save On Wikipedia ↗
AB0124
Clinical data
Other namesAB-0124; ABO124; ABO-124
Drug classSerotonin 5-HT2A receptor positive allosteric modulator
Identifiers
  • N-[2-(dimethylamino)ethyl]-4-(2-phenylethyl)piperidine-2-carboxamide
PubChem CID
Chemical and physical data
FormulaC18H29N3O
Molar mass303.450 g·mol−1
3D model (JSmol)
  • CN(C)CCNC(=O)C1CC(CCN1)CCC2=CC=CC=C2
  • InChI=1S/C18H29N3O/c1-21(2)13-12-20-18(22)17-14-16(10-11-19-17)9-8-15-6-4-3-5-7-15/h3-7,16-17,19H,8-14H2,1-2H3,(H,20,22)
  • Key:YAFSEZSVGMQXTE-UHFFFAOYSA-N

AB0124 is a serotonin 5-HT2A receptor positive allosteric modulator.[1][2][3] It is highly selective for potentiation of the serotonin 5-HT2A receptor, with no potentiation of the serotonin 5-HT2B and 5-HT2C receptors.[1][2] In addition, it showed no orthosteric agonistic activity at any of the serotonin 5-HT2 receptors.[1] AB0124 has been studied in combination with the serotonin 5-HT2 receptor agonist (R)-DOI in animal models of cocaine use disorder.[2][1] The chemical synthesis of AB0124 has been described.[3] The drug was patented in 2022[3] and was first described in the scientific literature by 2024.[2][1]

See also

References

  1. Merritt RF, Anastasio N, Zhou J, Cunningham K (January 2026). "ACNP 64th Annual Meeting: Poster Abstracts P292-583". Neuropsychopharmacology. 51 (Suppl 1): 243–409. doi:10.1038/s41386-025-02280-3. PMC 12783661. PMID 41507445.
  2. Bolinger AA, Zamora J, Merritt CR, Anastasio NC, Cunningham KA, Zhou J (March 2024). Discovery of novel serotonin 5-HT2A receptor positive allosteric modulators (PDF). 16TH Annual Behavior, Biology, and Chemistry: Translational Research in Substance Use Disorders, San Antonio, Texas | Embassy Landmark | 22-24 March 2024. Synthesizing and screening novel small molecules, we identified potent positive allosteric modulators (PAMs) of 5-HT2AR. Further analysis and comparison against CNS receptors, channels, and transporters led to the identification of AB0124 a potential candidate with high specificity. This compound has demonstrated functional increases in 5-HT-induced Ca2+ release at the micromolar level for the 5-HT2AR over other serotonin receptors. With promising in vitro pharmacological and physicochemical profiles, our novel 5-HT2AR PAMs hold potential as neurotherapeutics for [cocaine use disorder (CUD)].
  3. WO 2023/023287A1, Zhou J, Cunningham KA, Bolinger AA, Anastasio NC, "Novel heterocyclic compounds as serotonin (5-ht) 5-ht2a and 5-ht2c receptor positive allosteric modulators", issued 23 February 2023, assigned to University of Texas System, University of Texas at Austin